Characterization of drug –resistance profiles to directly acting agents in hepatitis C virus naive patients

ABSTRACT

Background: The development of direct-acting antiviral agents [DAAs] has revolutionized the treatment of HCV infection. The main challenge to HCV effective treatment with daas is the emergence of HCV drug-resistant variants. Detection of resistance associated variants is of importance in clinical settings in order to optimize DAA regimens, maximize success rates and reduce the impact of treatment failure